Every material Form 8-K Tenon Medical, Inc. has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tenon Medical, Nasdaq-listed medical device company, obtained a waiver from an institutional investor that lets it increase the number of shares it can sell under its at-the-market offering, in exchange for a new warrant to buy 125,000 shares at $5.02 per share. The company also agreed to register resale of the warrant shares, which may add shares available for sale into the market.
On October 16, 2026, the investor waived restrictions in its August 27, 2026 purchase agreement to allow a larger at-the-market offering under the August 11, 2026 sales agreement with A.G.P./Alliance Global Partners.
The investor received a Series B warrant for up to 125,000 shares at $5.02 per share, expiring September 14, 2031.
The restriction period under Section 4.12(a) was extended by 15 days, to 75 days after the Effective Date.
The company must file a resale registration statement on Form S-3 within 60 calendar days of the waiver.
Tenon Medical said holders exercised 572,179 existing warrants at $5.02 per share, bringing gross proceeds of $2,872,338.58, and received new five-year warrants for 858,269 shares at the same price. The deal was announced September 11, 2026 and closed September 14, 2026, with the company stating it will use the proceeds for working capital and general corporate purposes. Shareholders may face dilution if the new warrants are exercised, and the company agreed to register the resale of the underlying shares.
Existing warrants for 572,179 shares were exercised at $5.02 per share, with gross proceeds of $2,872,338.58, according to the filing.
New Series B warrants cover up to 858,269 shares, equal to 150% of the shares issued on exercise, with a $5.02 exercise price and a five-year term.
WallachBeth Capital LLC, the financial advisor, will receive a cash fee of 7% of gross proceeds plus legal expense reimbursement up to $65,000.
Tenon must file a resale registration statement within 30 calendar days of September 11, 2026 and seek effectiveness within 60 days, or 90 days if the SEC conducts a full review.
Tenon Medical said it repaid in full its original issue discount senior convertible promissory notes, with an aggregate principal balance of approximately $5.16 million, ahead of their September 11, 2026 maturity date. The company says the repayment removes the potential for the notes to convert into common stock at a discount to market prices, which it describes as reducing potential dilution for shareholders.
Notes with approximately $5.16 million aggregate principal balance repaid in full
Notes were issued on March 11, 2026 and were due September 11, 2026
Company states the repayment reduces potential dilution from discounted conversion into common stock
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tenon Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →